169 related articles for article (PubMed ID: 33015970)
21. Unraveling the interplay between senescent dermal fibroblasts and cutaneous squamous cell carcinoma cell lines at different stages of tumorigenesis.
Toutfaire M; Dumortier E; Fattaccioli A; Van Steenbrugge M; Proby CM; Debacq-Chainiaux F
Int J Biochem Cell Biol; 2018 May; 98():113-126. PubMed ID: 29550586
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
23. β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway.
Hu T; Gao Y
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32010942
[TBL] [Abstract][Full Text] [Related]
24. Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma.
Ji H; Niu X; Yin L; Wang Y; Huang L; Xuan Q; Li L; Zhang H; Li J; Yang Y; An W; Zhang Q
Cell Physiol Biochem; 2018; 45(3):951-961. PubMed ID: 29428948
[TBL] [Abstract][Full Text] [Related]
25. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
26. Soluble CXCL16 promotes TNF-α-induced apoptosis in DLBCL via the AMAD10-NF-κB regulatory feedback loop.
Yang H; Qiu B; Chen S; Xun Y; Pan Y; Chen M; Li WX; Liao W; El-Ashram S; Yang A; Liu F
Cell Biol Int; 2019 Aug; 43(8):863-874. PubMed ID: 31033093
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.
Wu C; Wu X; Zhang X; Chai Y; Guo Q; Li L; Yue L; Bai J; Wang Z; Zhang L
Int J Clin Exp Med; 2015; 8(9):15173-81. PubMed ID: 26629001
[TBL] [Abstract][Full Text] [Related]
28. Genotoxic Stress-Induced Senescence.
Fan DNY; Schmitt CA
Methods Mol Biol; 2019; 1896():93-105. PubMed ID: 30474843
[TBL] [Abstract][Full Text] [Related]
29. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
30. Stress-induced premature senescence (SIPS)--influence of SIPS on radiotherapy.
Suzuki M; Boothman DA
J Radiat Res; 2008 Mar; 49(2):105-12. PubMed ID: 18219184
[TBL] [Abstract][Full Text] [Related]
31. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
[TBL] [Abstract][Full Text] [Related]
33. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
34. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma.
Deng L; Jiang L; Tseng KF; Liu Y; Zhang X; Dong R; Lu Z; Wang X
Cancer Biomark; 2018; 23(2):157-164. PubMed ID: 30175971
[TBL] [Abstract][Full Text] [Related]
35. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
36. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
[TBL] [Abstract][Full Text] [Related]
37. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
[TBL] [Abstract][Full Text] [Related]
38. [Prognostic Value of CD14
Wu CX; Qiang M; Hao JQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):816-819. PubMed ID: 31204937
[TBL] [Abstract][Full Text] [Related]
39. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
40. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
